Glympa 25/5

Presentation: Each film-coated tablet contains 25 mg of empagliflozin and 5 mg of linagliptin.

Indications:Glympa is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.  

Dosage and Administration:The recommendeddose is one tablet (25 mg empagliflozin and 5 mg linagliptin) once daily, taken in the morning, with or without food. Renal function should be assessed before initiating Glympa and periodically thereafter. Glympa should not be initiated if eGFR is below 45 mL/min/1.73 m². Discontinue Glympa if eGFR falls below 45 mL/min/1.73 m².

Side Effects: Common side effects may include urinary tract infections and nasopharyngitis. Hypoglycemia may occur when used in combination with insulin or insulin secretagogues.

Precautions: Glympa is contraindicated in patients with severe renal impairment, end-stage renal disease, or dialysis, and in patients with a history of hypersensitivity reactions to empagliflozin or linagliptin. Assess renal function before initiating and during therapy. Use with caution in patients with risk factors for ketoacidosis and monitor for signs and symptoms of urinary tract infections.

Storage: Store below 30°C, protected from light and moisture. Keep out of reach of children.

Important Note: This information is for general knowledge and informational purposes only, and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.